Table 1 Current trials for CAR-T cell therapy in autoimmune diseases.
Target | Conditions | NTC | Phase | Sponsor |
|---|---|---|---|---|
CD19 | Severe, refractory systemic lupus erythematosus | NCT05869955 | Phase 1 | Bristol-Myers Squibb |
CD19 | Systemic Lupus Erythematosus | NCT05765006 | Phase 1 | Shanghai Ming Ju Biotechnology Co., Ltd. |
CD19 | Systemic Lupus Erythematosus | NCT03030976 | Phase 1 | Shanghai GeneChem Co., Ltd. |
CD19 | Refractory Systemic Lupus Erythematosus | NCT06189157 | Phase 1/2 | Miltenyi Biomedicine GmbH |
CD19 | Refractory Lupus nephritis | NCT05938725 | Phase 1 | Kyverna Therapeutics |
CD19 | Systemic lupus erythematosuslupus nephritis | NCT05798117 | Phase 1/2 | Novartis Pharmaceuticals |
CD19 | Systemic Lupus Erythematosus | NCT06121297 | Phase 1/2 | Cabaletta Bio |
CD19 | Refractory/Moderate-to-severe Systemic Lupus Erythematosus | NCT06106906 | Phase 1/2 | Wuhan Union Hospital, China |
CD19/BCMA | Relapsed/refractory systemic lupus erythematosus | NCT05474885 | Phase 1 | iCell Gene Therapeutics |
CD19/BCMA | Refractory systemic lupus erythematosus | NCT05846347 | Phase 1 | Zhejiang University |
CD19/CD20 | Refractory Systemic Lupus Erythematosus | NCT06153095 | Phase 1/2 | ImmPACT Bio |
CD19 | Idiopathic Inflammatory Myopathy Dermatomyositis Anti-Synthetase-Syndrome Immune-Mediated Necrotizing Myopathy | NCT06154252 | Phase 1/2 | Cabaletta Bio |
CD19 | Relapsing/Progressive Forms of Multiple Sclerosis | NCT06220201 | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
CD19 | Non-relapsing and Progressive Forms of Multiple Sclerosis | NCT06138132 | Phase 1 | Stanford University |
CD19 | Refractory myasthenia gravis | NCT05828225 | Phase 1 | Zhejiang University |
CD19 | Refractory Generalized Myasthenia Gravis | NCT06193889 | Phase 2 | Kyverna Therapeutics |
BCMA | Generalised myasthenia gravis | NCT04146051 | Phase 2 | Cartesian Therapeutics |
